Stay updated with breaking news from Acerus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cerus Co. (NASDAQ:CERS – Get Rating) SVP Carol Moore sold 28,513 shares of the company’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $5.04, for a total value of $143,705.52. The transaction was disclosed in a legal filing with the SEC, which is accessible […]
UBS Group AG grew its holdings in shares of Cerus Co. (NASDAQ:CERS – Get Rating) by 1,377.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 615,050 shares of the biotechnology company’s stock after acquiring an additional 573,420 shares during the […]
Aytu BioPharma, Inc.: Aytu BioPharma Divests U.S. Rights to Natesto to Acerus Pharma Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU) a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the signing of an agreement with Acerus Pharmaceuticals Corporation (ASP)(ASPCF) whereby Acerus will acquire all remaining rights to Nate...